| Atezolizumab |
Locally advanced or metastatic UC as monotherapy Locally advanced or metastatic NSCLC after prior chemotherapy Unresectable locally advanced or metastatic TNBC (in combination with nab-paclitaxel)
| hypothyroidism (very common in combination therapy, common as monotherapy) | hyperthyroidism, diabetes mellitus, adrenal insufficiency | hypophysitis | [71] |
| Avelumab |
| hypothyroidism | adrenal insufficiency, hyperthyroidism, thyroiditis, autoimmune thyroiditis, adrenocortical insufficiency acute, autoimmune hypothyroidism, hypopituitarism, type 1 diabetes mellitus | - | [4] |
| Durvalumab |
| hypothyroidism, hyperthyroidism | adrenal insufficiency, type 1 diabetes mellitus | hypophysitis / hypopituitarism, diabetes insipidus | [37] |
| Ipilimumab |
Advanced melanoma (as monotherapy/in combination with ipilimumab) Adjuvant treatment of melanoma NSCLC as monotherapy RCC relapsed or refractory cHL after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin SCCHN Urothelial Carcinoma
| hypothyroidism, hyperthyroidism | adrenal insufficiency, hypopituitarism, hypophysitis, thyroiditis, diabetes mellitus | diabetic ketoacidosis | [57] |
| Pemprolizumab Monotherapy |
| hypothyroidism, hyperthyroidism | adrenal insufficiency, hypophysitis, thyroiditis | - | [45] |
| Pemprolizumab Combination with chemotherapy |
| hypothyroidism, hyperthyroidism | hypophysitis, thyroiditis, adrenal insufficiency | - | [45] |
| Pemprolizumab Combination with axitinib |
| hypothyroidism, hyperthyroidism, hypophysitis, thyroiditis, adrenal insufficiency | - | - | [45] |
![Endocrine parameters that should be monitored in patients during monoclonal antibody treatment. A – endocrine side effects management algorithm [77], B – proposition of endocrine inspection during ICPi treatment [36]*TSH and FT4 measurement could be done each week during the first 2 months of ICPi treatment**If there is no corticosteroid treatmentAbbreviations: ICPi: Immune checkpoint inhibitor, TSH: Thyroid-stimulating hormone, FT4: Free thyroxine, ACTH: Adrenocorticotropic hormone, HbA1c: Hemoglobin A1c, LLN: below limit of normal, ULN: upper limit of normal, IV: intravenous, PO: per os.](https://sciendo-parsed.s3.eu-central-1.amazonaws.com/647088b271e4585e08a9f607/j_01.3001.0014.8889_fig_001.jpg?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=AKIA6AP2G7AKOUXAVR44%2F20251008%2Feu-central-1%2Fs3%2Faws4_request&X-Amz-Date=20251008T171319Z&X-Amz-Expires=3600&X-Amz-Signature=c692fb3d33db6e88fcba9a4bf8d62653461d23120339cfb3d5cf75a31b35bfdf&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)